CO4970782A1 - Terapia combinada para el tratamiento del sida - Google Patents

Terapia combinada para el tratamiento del sida

Info

Publication number
CO4970782A1
CO4970782A1 CO98066470A CO98066470A CO4970782A1 CO 4970782 A1 CO4970782 A1 CO 4970782A1 CO 98066470 A CO98066470 A CO 98066470A CO 98066470 A CO98066470 A CO 98066470A CO 4970782 A1 CO4970782 A1 CO 4970782A1
Authority
CO
Colombia
Prior art keywords
aids
treatment
combined therapy
abacavir
nelfinavir
Prior art date
Application number
CO98066470A
Other languages
English (en)
Inventor
Joseph P Vacca
H Lin Jiunn
C Yeh Kuang
Jeffrey A Chodakewitz
Paul J Deutsch
William D Ju
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9807938.7A external-priority patent/GB9807938D0/en
Priority claimed from GBGB9819590.2A external-priority patent/GB9819590D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of CO4970782A1 publication Critical patent/CO4970782A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Abstract

Una composición que contiene el Compuesto A de la fórmula y uno o más agentes antiretrovirales seleccionados entre Zidovudina, Lamivudina, Estavudina, DMP-266, Ritonavir, Nelfinavir, Abacavir, Indinavir, 141-W94, o Delavirdina; y sales o ésteres de ellos farmacéuticamente aceptables.1Un proceso para hacer una composición que comprende combinar el Compuesto A y uno o más agentes antiretrovirales seleccionados entre Zidovudina, Lamivudina, Estavudina, DMP-266, Ritonavir, Nelfinavir, Abacavir, Indinavir, 141-W94, o Delavirdina; y ésteres o sales de ellos farmacéuticamente aceptables.
CO98066470A 1997-11-13 1998-11-11 Terapia combinada para el tratamiento del sida CO4970782A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6542197P 1997-11-13 1997-11-13
GBGB9807938.7A GB9807938D0 (en) 1998-04-15 1998-04-15 Combination therapy for the treatment of AIDS
US9094098P 1998-06-26 1998-06-26
GBGB9819590.2A GB9819590D0 (en) 1998-09-08 1998-09-08 Combination therapy for the treatment of aids

Publications (1)

Publication Number Publication Date
CO4970782A1 true CO4970782A1 (es) 2000-11-07

Family

ID=27451773

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98066470A CO4970782A1 (es) 1997-11-13 1998-11-11 Terapia combinada para el tratamiento del sida

Country Status (24)

Country Link
EP (1) EP1044000B1 (es)
JP (1) JP2001522889A (es)
KR (1) KR20010032055A (es)
CN (1) CN1285747A (es)
AR (1) AR013758A1 (es)
AT (1) ATE218866T1 (es)
AU (1) AU749795B2 (es)
BG (1) BG104507A (es)
BR (1) BR9814146A (es)
CA (1) CA2309164A1 (es)
CO (1) CO4970782A1 (es)
DE (1) DE69806062T2 (es)
EA (1) EA200000513A1 (es)
ES (1) ES2177103T3 (es)
HU (1) HUP0100365A3 (es)
ID (1) ID24922A (es)
IL (1) IL135994A0 (es)
IS (1) IS5481A (es)
NO (1) NO20002481L (es)
PE (1) PE20000020A1 (es)
PL (1) PL340430A1 (es)
SK (1) SK6842000A3 (es)
TR (1) TR200001938T2 (es)
WO (1) WO1999025352A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US7462733B2 (en) 2001-07-30 2008-12-09 University Of Southern California Preparation and use of α-keto phosphonates
EP3025718A1 (en) 2003-01-14 2016-06-01 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
GB2400553A (en) * 2003-04-14 2004-10-20 Cipla Ltd Antiviral pharmaceutical combination of lamivudine, stavudine and efavirenz, or derivatives thereof
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ288312B6 (en) * 1993-12-15 2001-05-16 Merck & Co Inc HIV-protease inhibitors and pharmaceutical preparations in which they are comprised

Also Published As

Publication number Publication date
PL340430A1 (en) 2001-02-12
AR013758A1 (es) 2001-01-10
PE20000020A1 (es) 2000-01-27
IS5481A (is) 2000-05-09
CA2309164A1 (en) 1999-05-27
JP2001522889A (ja) 2001-11-20
HUP0100365A2 (hu) 2002-05-29
EA200000513A1 (ru) 2000-10-30
ES2177103T3 (es) 2002-12-01
NO20002481L (no) 2000-07-12
IL135994A0 (en) 2001-05-20
DE69806062D1 (de) 2002-07-18
KR20010032055A (ko) 2001-04-16
DE69806062T2 (de) 2003-03-20
AU1522599A (en) 1999-06-07
ATE218866T1 (de) 2002-06-15
BG104507A (bg) 2001-03-30
TR200001938T2 (tr) 2001-07-23
HUP0100365A3 (en) 2002-06-28
SK6842000A3 (en) 2000-12-11
AU749795B2 (en) 2002-07-04
ID24922A (id) 2000-08-31
EP1044000B1 (en) 2002-06-12
WO1999025352A1 (en) 1999-05-27
CN1285747A (zh) 2001-02-28
EP1044000A1 (en) 2000-10-18
NO20002481D0 (no) 2000-05-12
BR9814146A (pt) 2000-10-03

Similar Documents

Publication Publication Date Title
NL960002I2 (nl) Nieuwe taxolderivaten, werkwijzen ter bereiding daarvan en farmaceutische preparaten, die deze bevatten.
MX9204625A (es) Composicion farmaceutica para el tratamiento de una especie de mamifero, que sufre de deficiencia cardiaca congestiva.
ES2148229T3 (es) Eteres y tioeteres en la posicion 17 de 4-aza-esteroides.
ECSP003682A (es) Compuestos para el tratamiento de la isquemia
DE69124371D1 (de) Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
IT8021794A0 (it) Pinza per l'applicazione di graffe all'ovidotto.
TR199800077T1 (xx) Kontroll� ��z�len paroksetin terkipleri.
AR005009A1 (es) Monohidrato del cdch, procedimiento para su produccion , composiciones antibacteriales que lo contienen, uso del monohidrato del cdch para la manufactura de medicamentos.
ES2133426T3 (es) Combinaciones de productos activos fungicidas.
NO885670D0 (no) Fortilsetning og for som inneholder denne tilsetning.
NL7713091A (nl) Derivaten van de trypsine-callicreine-remmer uit runderorganen (bpti) met proteasen remmende werking en antiflogistische werking, alsmede de bereiding van dergelijke derivaten en preparaten, die deze derivaten bevatten.
MX9306311A (es) Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
CO4970782A1 (es) Terapia combinada para el tratamiento del sida
CO5050328A1 (es) Sistema solvente para la mejor penetracion de compuestos farmaceuticos
SE8307146D0 (sv) 7-oxabicykloheptan-substituerade aminoprostaglandinanaloger
UY25068A1 (es) Formas de dosificación de sertralina de liberación retardada
CO4940435A1 (es) Sal de hemisulfato del (1s,4r)-cis-4-[2-amino-6- (ciclopropilamino)-9h-purin-9-il]-2-ciclopenten-1-metanol o un solvato del mismo
DE69533876D1 (de) Zusammensetzung für die gentherapeutische Behandlung von Koronar-Arterienerkrankungen.
FI793261A (fi) Farmaceutisk komposition som innehaoller 3,4-dihydro-3-oxo-2-kinoxaliner
DK88087A (da) Tricyklisk 5-(3-chlor-6-methyl-5,5-dioxo-6,11-dihydro-dibenzo-(c,f)-(1,2)-thiazepin-11-yl)-amino-pentansyrederivat, fremgangsmaade til fremstilling deraf og farmaceutiske midler indeholdende dem
ES2156616T3 (es) (r)-5-bromo-n-(1-etil-4-metilhexahidro-1h-1,4-diazepan-6-il)-2-metoxi-6-metilamino-3-piridincarboxamida, procedimiento para su produccion y composicion medicinal que la contiene.
IT8721394A0 (it) Procedimento per la rifinizione di pellame, cuoio e simili substrati fibrosi.
ES2187030T3 (es) Una nueva sal.
CO4700430A1 (es) Terapia combinada para inspeccion por vih
IE43725L (en) 5-methoxy-6-halotryptamines.